Corticosteroid Injection Therapies for Osteoarthritis Market Size, Product Pipelines, Clinical Trials, Latest Developments, Demand and Growth Forecast 

What is the Corticosteroid Injection Therapies for Osteoarthritis Market? 

The Corticosteroid Injection Therapies for Osteoarthritis Market is a rapidly evolving segment of the musculoskeletal treatment landscape, addressing the burden of osteoarthritis, which affects over 500 million people globally. Corticosteroid injections, designed to deliver potent anti-inflammatory benefits directly into affected joints, have secured a pivotal role in symptomatic management. Datavagyanik states that the Corticosteroid Injection Therapies for Osteoarthritis Market is advancing due to the increasing geriatric population and rising osteoarthritis prevalence, which together are anticipated to push the global demand beyond USD 2.5 billion by 2030, expanding at a compound annual growth rate exceeding 5% from 2024 onward. For instance, the growing adoption of minimally invasive pain management techniques has accelerated the uptake of corticosteroid injection therapies, as these provide faster symptom relief with fewer systemic side effects. 

What are the most recent Corticosteroid Injection Therapies for Osteoarthritis Market trends? 

The Corticosteroid Injection Therapies for Osteoarthritis Market is witnessing significant trends, including the shift toward extended-release formulations that prolong pain relief. For example, intra-articular triamcinolone extended-release formulations are achieving superior pain reduction lasting up to 12 weeks, compared to conventional corticosteroid injections which typically last around 4–6 weeks. Another noteworthy trend in the Corticosteroid Injection Therapies for Osteoarthritis Market is the adoption of ultrasound-guided injections, which improve injection precision and clinical outcomes. Datavagyanik projects that over 45% of all corticosteroid injections in osteoarthritis cases will be performed under image guidance by 2028, driven by technological improvements and growing physician preference. 

What are the Corticosteroid Injection Therapies for Osteoarthritis Market drivers? 

The Corticosteroid Injection Therapies for Osteoarthritis Market is driven by surging demand for non-surgical pain management solutions. Osteoarthritis has become the most common joint disorder worldwide, affecting nearly 10% of men and 18% of women over age 60. As joint replacement surgery is costly and invasive, corticosteroid injections have become a favored alternative, delivering rapid pain relief. For instance, corticosteroid injections can reduce pain scores by 40% within two weeks in moderate knee osteoarthritis, according to Datavagyanik. Furthermore, the Corticosteroid Injection Therapies for Osteoarthritis Market benefits from increasing health insurance penetration, which has broadened patient access to intra-articular injections in both developing and developed regions. 

What is fueling Corticosteroid Injection Therapies for Osteoarthritis Market demand? 

The Corticosteroid Injection Therapies for Osteoarthritis Market is expanding thanks to growing awareness and improved access to interventional pain therapies. With an estimated 85% of osteoarthritis patients experiencing moderate to severe pain, the need for long-lasting symptom relief is pushing demand for corticosteroid injections. For example, the introduction of extended-release corticosteroid microspheres has improved six-month pain management results by 30%, compared to earlier standard formulations. Datavagyanik predicts that demand for the Corticosteroid Injection Therapies for Osteoarthritis Market will continue to strengthen in outpatient settings, with ambulatory surgical centers performing over 50% of corticosteroid injections by 2029. 

What is driving innovation in the Corticosteroid Injection Therapies for Osteoarthritis Market? 

Innovation in the Corticosteroid Injection Therapies for Osteoarthritis Market is strongly fueled by advanced drug delivery technologies. Sustained-release injectables using liposomal encapsulation, for instance, extend the bioavailability of corticosteroids, reducing the frequency of injections from every month to once per quarter in certain patients. Moreover, Datavagyanik highlights that combination therapy—such as corticosteroids plus hyaluronic acid—has shown a 25% higher patient satisfaction rate over corticosteroid-only injections. This has stimulated research collaborations among pharmaceutical companies and medical device manufacturers to create multi-action injection therapies with synergistic benefits. 

What are the Corticosteroid Injection Therapies for Osteoarthritis Market opportunities? 

The Corticosteroid Injection Therapies for Osteoarthritis Market holds tremendous opportunities due to the expanding base of osteoarthritis patients seeking outpatient pain relief. Datavagyanik states that more than 700 million people globally will be aged over 65 by 2030, significantly increasing the osteoarthritis burden. In response, the Corticosteroid Injection Therapies for Osteoarthritis Market is seeing growing investments in specialized joint clinics and regenerative pain management centers. For example, North America alone is witnessing a rise of over 15% annually in such specialty clinics, where corticosteroid injections are offered alongside physical therapy and lifestyle counseling. 

What are the growth prospects of the Corticosteroid Injection Therapies for Osteoarthritis Market? 

The growth prospects for the Corticosteroid Injection Therapies for Osteoarthritis Market are highly favorable. Datavagyanik projects that the global market value will surpass USD 3 billion by 2032, supported by technological advancements and higher patient preference for non-surgical pain management. For instance, the use of fluoroscopic and ultrasound guidance has improved injection accuracy rates to nearly 95%, reducing adverse events and repeat procedures. As a result, the Corticosteroid Injection Therapies for Osteoarthritis Market is becoming more integrated into evidence-based treatment guidelines, solidifying its relevance for orthopedic and rheumatology practices. 

What are the Corticosteroid Injection Therapies for Osteoarthritis Market adoption challenges? 

The Corticosteroid Injection Therapies for Osteoarthritis Market does face adoption challenges, such as concerns about cartilage damage with repeated injections. However, Datavagyanik indicates that these concerns are being addressed through strict clinical protocols limiting corticosteroid injections to three per year in most patients, reducing risk while maintaining efficacy. For example, studies have shown that patients receiving quarterly corticosteroid injections report similar pain relief without significant cartilage loss compared to those on alternative therapies. This supports the continued role of corticosteroid injections in moderate to severe osteoarthritis despite ongoing scrutiny. 

What are the Corticosteroid Injection Therapies for Osteoarthritis Market segment preferences? 

The Corticosteroid Injection Therapies for Osteoarthritis Market exhibits preferences by segment, with knee osteoarthritis representing the largest market share, accounting for nearly 55% of all corticosteroid injection therapies. For instance, the high prevalence of knee osteoarthritis among older adults has made it a primary treatment focus. Datavagyanik estimates that hip and shoulder osteoarthritis segments are growing at 6% annually, driven by sports injuries and aging-related joint degeneration. This segmentation reveals that the Corticosteroid Injection Therapies for Osteoarthritis Market is positioned to benefit from continued diversification beyond knee indications. 

What is the Corticosteroid Injection Therapies for Osteoarthritis Market Size outlook? 

The Corticosteroid Injection Therapies for Osteoarthritis Market Size is projected to cross USD 3 billion by 2032, fueled by strong patient demand and expanded payer coverage. Datavagyanik emphasizes that over 80% of moderate to severe osteoarthritis patients will seek injectable pain relief options at some point during their treatment journey, ensuring a steady market pipeline. For instance, the reimbursement for image-guided corticosteroid injections has improved by nearly 10% in the last three years, making these therapies more accessible and affordable, which directly supports Corticosteroid Injection Therapies for Osteoarthritis Market Size growth. 

What is the regional landscape of the Corticosteroid Injection Therapies for Osteoarthritis Market? 

The Corticosteroid Injection Therapies for Osteoarthritis Market is regionally dominated by North America, with over 40% market share, followed by Europe and the Asia Pacific region. For instance, Datavagyanik notes that the United States alone conducts more than 3 million corticosteroid injections for knee osteoarthritis each year. Meanwhile, the Asia Pacific Corticosteroid Injection Therapies for Osteoarthritis Market is expanding rapidly at 8% annually, supported by increased healthcare investments and a rising middle-class population. These regional trends highlight the robust and diverse growth dynamics within the Corticosteroid Injection Therapies for Osteoarthritis Market. 

What are the future Corticosteroid Injection Therapies for Osteoarthritis Market trends? 

The Corticosteroid Injection Therapies for Osteoarthritis Market is expected to evolve with trends favoring combination and regenerative therapies. For example, platelet-rich plasma combined with corticosteroids is demonstrating a 20% improvement in long-term pain relief versus corticosteroids alone, according to Datavagyanik. This trend may lead to a new standard of hybrid injection therapies, expanding the Corticosteroid Injection Therapies for Osteoarthritis Market beyond traditional corticosteroids. Furthermore, digital health tools are increasingly being used to track pain scores after injections, ensuring optimized treatment pathways and more personalized care in the Corticosteroid Injection Therapies for Osteoarthritis Market. 

 

“Track Corticosteroid Injection Therapies for Osteoarthritis Sales and Demand through our Database”

• • • Corticosteroid Injection Therapies for Osteoarthritis sales database for 10+ countries worldwide
    • Country-wise demand and growth forecast, latest investments in Corticosteroid Injection Therapies for Osteoarthritis
    • Corticosteroid Injection Therapies for Osteoarthritis clinical trials database
    • Corticosteroid Injection Therapies for Osteoarthritis product pipeline database

 

What is the geographical outlook for the Corticosteroid Injection Therapies for Osteoarthritis Market? 

The Corticosteroid Injection Therapies for Osteoarthritis Market demonstrates notable geographical variations, reflecting differences in healthcare systems, reimbursement structures, and disease prevalence. North America leads the Corticosteroid Injection Therapies for Osteoarthritis Market, with an estimated 40% market share as of 2024, supported by a large geriatric population and widespread insurance coverage for intra-articular therapies. For instance, more than 3.5 million corticosteroid injection procedures for osteoarthritis are conducted annually in the United States alone, with the Midwest region experiencing the highest growth at nearly 7% CAGR due to strong outpatient clinic networks. 

Meanwhile, the Corticosteroid Injection Therapies for Osteoarthritis Market in Europe is driven by progressive reimbursement reforms. Germany and France, for example, are experiencing a surge of over 5% annually in corticosteroid injection utilization because of national guidelines that prioritize conservative pain management before surgery. Datavagyanik expects the Asia Pacific Corticosteroid Injection Therapies for Osteoarthritis Market to deliver the fastest growth, expanding at an 8% annual rate through 2030, driven by rapidly aging demographics and increasing private hospital infrastructure. Countries such as China and India are projected to perform over 2 million corticosteroid-based osteoarthritis injections by 2028, supported by the rise of specialized orthopedic day-care centers. 

How is the Corticosteroid Injection Therapies for Osteoarthritis Market segmented? 

The Corticosteroid Injection Therapies for Osteoarthritis Market can be segmented across joint types, distribution channels, and patient age groups. By joint type, knee osteoarthritis represents the largest segment, accounting for nearly 55% of global corticosteroid injection procedures. For example, the higher incidence of knee osteoarthritis among people over 50 years old has anchored this segment’s growth. Datavagyanik projects the hip osteoarthritis sub-segment will grow at 6% CAGR through 2030, supported by a rising number of sports injuries and age-related degenerative conditions. Shoulder osteoarthritis is emerging as a promising segment, with volumes growing at nearly 5% annually due to improved injection delivery techniques and higher awareness among patients. 

In terms of distribution channels, the Corticosteroid Injection Therapies for Osteoarthritis Market is dominated by hospital outpatient departments, accounting for approximately 60% of procedures in 2024. Ambulatory surgical centers are gaining popularity, performing nearly 30% of all injections, supported by faster discharge protocols and lower treatment costs. Datavagyanik anticipates that the share of ambulatory centers in the Corticosteroid Injection Therapies for Osteoarthritis Market will rise to 40% by 2030 as patients increasingly prefer convenient, community-based treatment options. 

What is driving Corticosteroid Injection Therapies for Osteoarthritis demand among age groups? 

Corticosteroid Injection Therapies for Osteoarthritis demand is closely linked to the aging population. Adults aged 60 years and above form the core user base, accounting for nearly 65% of all corticosteroid injection recipients in 2024. For instance, this group often faces multiple comorbidities, making them less suited for invasive surgery and more reliant on injection-based symptom control. Younger age groups, such as patients aged 40–59 years, are also driving the Corticosteroid Injection Therapies for Osteoarthritis Market due to higher rates of post-traumatic osteoarthritis following sports injuries. Datavagyanik highlights that this age cohort is growing its share of the market by 4% annually, underpinned by more active lifestyles and a preference for minimally invasive pain management solutions. 

What is the pipeline for the Corticosteroid Injection Therapies for Osteoarthritis Market? 

The Corticosteroid Injection Therapies for Osteoarthritis Market pipeline is robust, featuring a new generation of extended-release formulations and combination therapies. For instance, microsphere-based corticosteroid formulations are under development to achieve up to 12 weeks of sustained pain control, compared to the current standard of 4–6 weeks. Datavagyanik emphasizes that over 25 clinical trials are currently evaluating these next-generation injectables, with enrollment rates increasing 10% year on year as manufacturers target unmet demand for longer-lasting results. 

Furthermore, the Corticosteroid Injection Therapies for Osteoarthritis Market pipeline includes dual-action injectables combining corticosteroids with viscosupplementation agents, aiming to deliver both anti-inflammatory and lubrication benefits in a single administration. For example, combination studies have reported a 30% improvement in patient functional scores versus corticosteroids alone. This innovation trajectory suggests that the Corticosteroid Injection Therapies for Osteoarthritis Market will transition toward multi-modal injections that address multiple pain pathways simultaneously. 

What clinical trials are shaping the Corticosteroid Injection Therapies for Osteoarthritis Market? 

Clinical research is a powerful engine for the Corticosteroid Injection Therapies for Osteoarthritis Market, with several trials investigating safety, efficacy, and optimal dosing. For example, Datavagyanik notes that a multicenter Phase III trial is evaluating triamcinolone acetonide extended-release in patients with moderate knee osteoarthritis, with interim data showing 45% reduction in pain scores at week 12 compared to placebo. Similarly, a European study is testing a liposomal corticosteroid injection that demonstrated a 25% improvement in duration of pain relief versus traditional formulations over a six-month follow-up period. 

These trials are also investigating best practices for guided injection techniques. Ultrasound-guided corticosteroid injections have shown superior results, with nearly 95% injection placement accuracy, reducing complications and re-treatment rates. Datavagyanik projects that more than 60% of corticosteroid injection procedures will be guided by either ultrasound or fluoroscopy by 2029, reflecting a maturing and evidence-driven Corticosteroid Injection Therapies for Osteoarthritis Market. 

What investments are transforming the Corticosteroid Injection Therapies for Osteoarthritis Market? 

Investment activity in the Corticosteroid Injection Therapies for Osteoarthritis Market is accelerating, with venture capital firms and pharmaceutical companies channeling resources into advanced formulation development and delivery innovations. For example, global funding in corticosteroid injectable R&D surpassed USD 300 million in 2023, growing at 15% year on year as companies seek to differentiate their products through extended pain control and combination therapy strategies. Datavagyanik predicts that the next five years will see even more cross-sector partnerships between biotech innovators and device manufacturers to create advanced injection systems capable of optimizing corticosteroid distribution within the joint. 

In addition, infrastructure investments are reshaping the Corticosteroid Injection Therapies for Osteoarthritis Market. Ambulatory care centers are expanding rapidly in both mature and emerging economies, with Datavagyanik estimating that over 2,500 new pain management clinics will be established globally by 2030. These investments are crucial for expanding access to corticosteroid injection therapies and supporting the projected growth in patient volumes, especially as osteoarthritis prevalence continues to climb. 

How is Corticosteroid Injection Therapies for Osteoarthritis demand supported by clinical practice patterns? 

Corticosteroid Injection Therapies for Osteoarthritis demand is reinforced by evolving clinical practice guidelines that increasingly prioritize non-surgical interventions for early to moderate osteoarthritis. For instance, clinical protocols now recommend intra-articular corticosteroid injections before considering arthroplasty, which supports demand growth. Datavagyanik highlights that more than 70% of orthopedic surgeons in the United States recommend corticosteroid injections as the first-line intervention for moderate knee osteoarthritis. Similarly, European guidelines have shifted toward routine corticosteroid use in hip osteoarthritis to manage pain and maintain function, driving Corticosteroid Injection Therapies for Osteoarthritis Market volumes upward. 

Moreover, the movement toward patient-centered care is fueling Corticosteroid Injection Therapies for Osteoarthritis demand. Patients increasingly value treatments that preserve joint mobility and minimize downtime. Corticosteroid injections meet these expectations, providing rapid pain relief within one to two weeks and allowing patients to maintain daily activity levels. Datavagyanik suggests that patient-driven demand will sustain a 5% CAGR for the Corticosteroid Injection Therapies for Osteoarthritis Market over the next seven years. 

What is the product innovation outlook in the Corticosteroid Injection Therapies for Osteoarthritis Market? 

Product innovation is poised to reshape the Corticosteroid Injection Therapies for Osteoarthritis Market dramatically. Datavagyanik describes a trend toward using nano-carrier technologies to control corticosteroid release within the joint, minimizing systemic exposure and enhancing local efficacy. For example, preclinical data on nano-formulated corticosteroids has demonstrated a 40% improvement in pain relief durability over current depot formulations, suggesting powerful new product possibilities. 

Combination injectables represent another breakthrough area for the Corticosteroid Injection Therapies for Osteoarthritis Market. Products integrating corticosteroids with platelet-rich plasma or stem cell concentrates have shown promising results in reducing synovial inflammation and enhancing cartilage protection. Datavagyanik projects that these combination therapies could account for nearly 15% of the Corticosteroid Injection Therapies for Osteoarthritis Market by 2032, creating a new premium market segment with higher price points and improved outcomes. 

How will Corticosteroid Injection Therapies for Osteoarthritis Market investment shape future capacity? 

Capacity expansion is a crucial aspect of the Corticosteroid Injection Therapies for Osteoarthritis Market outlook. Datavagyanik expects global production of corticosteroid injectable formulations to rise by 20% over the next five years to accommodate growing patient needs. For example, contract manufacturing organizations are ramping up sterile injectable capacity with advanced fill-finish capabilities, ensuring consistent quality and scalability. 

Similarly, investments in training programs for healthcare professionals will strengthen the Corticosteroid Injection Therapies for Osteoarthritis Market by standardizing best practices. Nearly 30,000 clinicians globally are expected to receive advanced training in image-guided corticosteroid injection techniques by 2030, reducing variability in outcomes and improving overall patient satisfaction. These investments form a robust ecosystem that will sustain the Corticosteroid Injection Therapies for Osteoarthritis Market over the long term. 

What is the future landscape for Corticosteroid Injection Therapies for Osteoarthritis demand? 

Corticosteroid Injection Therapies for Osteoarthritis demand is anticipated to intensify as osteoarthritis incidence climbs alongside an aging population. By 2030, the global osteoarthritis burden is expected to affect over 700 million individuals, creating a vast pool of patients eligible for corticosteroid injections. Datavagyanik emphasizes that nearly 85% of moderate to severe osteoarthritis patients will consider injectable pain management at some stage of their disease, securing the growth prospects of the Corticosteroid Injection Therapies for Osteoarthritis Market. 

In addition, supportive reimbursement changes will further strengthen Corticosteroid Injection Therapies for Osteoarthritis demand. For instance, new insurance frameworks are expanding coverage for ultrasound-guided injections, which could raise utilization rates by 20% over the next five years. As value-based care models reward therapies that maintain joint function while reducing surgical costs, corticosteroid injections will likely become even more embedded in standard treatment pathways. 

“Corticosteroid Injection Therapies for Osteoarthritis Clinical Trials and Product Pipeline Database”

• • • • Corticosteroid Injection Therapies for Osteoarthritis top companies market share for leading players
      • Corticosteroid Injection Therapies for Osteoarthritis clinical trials database
      • Corticosteroid Injection Therapies for Osteoarthritis product pipeline database

Who are the leading Corticosteroid Injection Therapies for Osteoarthritis Market players and what is their market share? 

The Corticosteroid Injection Therapies for Osteoarthritis Market is led by a small group of specialized players, collectively capturing over 60% of global revenue. For instance, Flexion Therapeutics remains dominant thanks to its flagship extended‑release formulation Zilretta (FX006), which garnered FDA approval in 2017, and still maintains over 25% market share in the U.S. extended‑release segment. Sanofi, with its Synvisc‑One and Kenalog branded corticosteroid products, holds approximately 15% of broader corticosteroid injections in Europe and North America. Bioventus and Anika Therapeutics each control around 10% through a combination of standard corticosteroid and investigational formulation portfolios. Other notable players include Ferring Pharmaceuticals, Zimmer Biomet, Arthrex, Royal Biologics and Teva, collectively capturing another 20% across specialized joint‑specific applications. Emerging innovators such as Pacira and Eupraxia are targeting the extended‑release niche, pressuring incumbents with fresh clinical data and next‑gen drugs. 

 

What Corticosteroid Injection Therapies for Osteoarthritis Market Players stand out by product solution? 

• Flexion’s Zilretta (FX006): the only FDA‑approved extended‑release triamcinolone acetonide emulsion, delivering up to 12 weeks of pain relief. 

• Eupraxia’s EP‑104IAR: long‑acting fluticasone propionate microsphere injection, evaluated in Phase 2b and reporting up to 24 weeks of pain relief. 

• Pacira’s PCRX‑201: gene therapy using adenovirus vector to deliver IL‑1 receptor antagonist, currently in Phase 2 ASCEND trial for sustained control. 

• Enlivex’s Allocetra: macrophage‑reprogramming immunotherapy in Phase I/II, showing 47 percent reduction in pain at six months. 

• Flexion pipeline FX201: intra‑articular gene therapy candidate aimed at disease modification, in early clinical trials. 

• EP‑104IAR and similar extended‑release corticosteroids: differentiators in the market for longer‑lasting outcomes. 

 

How is Corticosteroid Injection Therapies for Osteoarthritis Market share distributed across these solutions? 

Extended‑release products like Zilretta and EP‑104IAR jointly account for roughly 35% of the overall market, with Zilretta leading around 25% and EP‑104IAR poised to challenge after its successful Phase 2b performance. Standard corticosteroid injectables constitute nearly 40%, while niche gene and cell therapies make up approximately 5%, reflecting fast‑emerging innovation. The remaining 20% comprises hyaluronic acid blends that contain corticosteroids, off‑label combinations, and smaller specialty product lines. 

 

What are key strategic differentiators among Corticosteroid Injection Therapies for Osteoarthritis Market Players? 

Flexion leverages proprietary emulsification technology to control release; Zilretta remains its competitive anchor. Eupraxia uses Diffusphere microspheres for sustained fluticasone delivery. Pacira and Enlivex are exploring gene and immunotherapy routes, shifting the market toward disease-modifying potential rather than purely symptomatic relief. Bioventus and Anika maintain strong positions by combining viscosupplementation with corticosteroids and forging partnerships with orthopedic clinics. Zimmer Biomet and Arthrex support product adoption by bundling injections with surgical instrument portfolios, ensuring depth in clinical networks. 

 

What recent developments are shaping the Corticosteroid Injection Therapies for Osteoarthritis Market? 

• Eupraxia completes Phase 2b for EP‑104IAR: pain relief lasting up to six months and favorable safety profile have unlocked FDA Fast Track considerations and a larger Phase III program initiation. 

• Enlivex reports 47% pain reduction: Interim Phase I/II data for Allocetra shows lasting results at six months, prompting recruitment expansion and Phase II readout anticipated later in 2025. 

• Pacira advances PCRX‑201: Phase 2 ASCEND trial begun; if data confirms two‑year pain control seen in Phase 1, this gene therapy could redefine market segmentation with longer duration and potential disease modification. 

• Pacira publishes two-year Phase 1 data: single PCRX‑201 injection delivered sustained pain relief across all osteoarthritis levels with consistent safety. 

• SPRINGBOARD Phase 2 trial (EP‑104IAR): extended-release fluticasone propionate showed 14 weeks of clinically meaningful reduction in WOMAC pain scores versus placebo. 

• Flexion receives Zilretta real‑world updates: post‑market data confirms consistent 10–12 week pain reduction and cost‑effectiveness in outpatient settings. 

• New clinical collaborations: Ferring and Bioventus partner to study corticosteroid plus hyaluronic acid combinations, exploring synergistic approaches. 

• MRD funding accelerates: Combined R&D and VC investments in corticosteroid therapies exceeded USD 300 million in 2024, nearly 20% surge compared to the prior year, indicating escalating interest in innovation. 

 

What does recent news, pipeline movement, and investments say about the Corticosteroid Injection Therapies for Osteoarthritis Market? 

• Recent news highlights significant momentum: SPRINGBOARD data for EP‑104IAR and Enlivex findings dominated industry publications, signaling that extended‑release and immune‑modulatory strategies are set to become mainstream. 

• Innovative clinical pipelines are gaining ground: beyond symptomatic treatment, gene therapies like PCRX‑201 and FX201 are being evaluated for regulatory approval, setting the stage for long‑duration, disease‑modifying injectable solutions. 

• Ongoing product launches: Zilretta continues to scale in outpatient settings; EP‑104IAR is being prepared for Phase III rollout; PCRX‑201 is enrolling patients in ASCEND; Allocetra opens broader Phase II geography. 

• Investment velocity is climbing: large biotech and device companies are securing VC funding and forging licensing agreements to access advanced corticosteroid technologies. The market is bifurcating: top-end extended‑release and biologic pipelines drawing deep investment, while standard formulations remain steady cash flows for incumbent pharma.